SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy (Superman)

February 20, 2024 updated by: Canisius-Wilhelmina Hospital

The goal of this single blind placebo-controlled intervention study is to examine the impact of a supervised training program on disease-related quality of life and physical fitness in patient with advanced prostate cancer compared to usual care. The main question[s] it aims to answer are:

  • What is the impact of exercise on quality of life
  • What is the impact of exercise on physical fitness

Participants will have an individual training program with supervised training by physiotherapists.

Researchers will compare with usual care to see if advice about exercise has significant less effect than an supervised training program.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: stijn Elbers, MD
  • Phone Number: (+31)243657657
  • Email: s.elbers@cwz.nl

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Signed informed consent
  • Age > 18 years old
  • Able to read and complete questionnaires in Dutch
  • Proven histologically and /or radiologically metastatic prostate cancer (TxNxM1)

Exclusion Criteria:

  • Other cancers
  • Clinicians' judgement
  • Age >80 years old or not able to walk 400m
  • Structural exercise (moderate-intensity exercise more than 150 minutes a week) during the past 3 months
  • Musculoskeletal, cardiovascular, or neurological disorders that could inhibit them from exercising
  • Spinal cord compression, history of pathological fractures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: intervention
supervised training program for twelve weeks + usual care + advice about exercise
supervised training program for twelve weeks + usual care + advice about exercise
No Intervention: usual care
usual care + advice about exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of quality of life assessed with EPIC26 (0-100 points)
Time Frame: 6 months
To examine the impact of a supervised training program on disease-related quality of life in patient with advanced prostate cancer compared to usual care. The following questionnaire is used: Expanded Prostate Cancer Index Composite (EPIC26). With higher scores representing better disease-related quality of life.
6 months
change of quality of life assessed with EPIC26 (0-100 points)
Time Frame: 3 months
To examine the impact of a supervised training program on disease-related quality of life in patient with advanced prostate cancer compared to usual care. The following questionnaire is used: Expanded Prostate Cancer Index Composite (EPIC26). With higher scores representing better disease-related quality of life.
3 months
change of quality of life assessed with EORTC QLQ-C30 (0-100 points per scale)
Time Frame: 6 months
To examine the impact of a supervised training program on disease-related quality of life in patient with advanced prostate cancer compared to usual care. The following questionnaires are used: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (EORTC QLQ-C30). A higher score represents a higher response level. So a higher score for the functional scale represents a higher level of physical functioning but a higher score for the symptoms scale represents a higher level of symptoms.
6 months
change of quality of life assessed with EORTC QLQ-C30 (0-100 points per scale)
Time Frame: 3 months
To examine the impact of a supervised training program on disease-related quality of life in patient with advanced prostate cancer compared to usual care. The following questionnaires are used: European Organization for Research and Treatment for Cancer Quality of Life Questionnaire (EORTC QLQ-C30). A higher score represents a higher response level. So a higher score for the functional scale represents a higher level of physical functioning but a higher score for the symptoms scale represents a higher level of symptoms.
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change of physical fitness in maximum uptake of oxygen in ml/kg/min
Time Frame: 6 months
Assessment of the effectiveness of a supervised training program on cardiopulmonary fitness in patients with metastatic prostate cancer compared to usual care.
6 months
change of physical fitness in maximum uptake of oxygen in ml/kg/min
Time Frame: 3 months
Assessment of the effectiveness of a supervised training program on cardiopulmonary fitness and body composition in patients with metastatic prostate cancer compared to usual care.
3 months
change of physical fitness in fat percentage
Time Frame: 3 months
change in body composition in patients with metastatic prostate cancer compared to usual care.
3 months
change of physical fitness in fat percentage
Time Frame: 6 months
change in body composition in patients with metastatic prostate cancer compared to usual care.
6 months
change of fitness assessed with IPAQ-sh (categories (1-3) and continues (MET-minutes))
Time Frame: 3 months
To examine the impact of a supervised training program on disease-related quality of life in patient with advanced prostate cancer compared to usual care. The following questionnaires are used: Short Hebrew International Physical Activity Questionnaire (IPAQ-sh). Both categorical and continuous indicators of physical activity will be used from the IPAQ short form. There are three categories:1. inactive, 2. minimally active, 3. HEPA active (health enhancing physical activity; a high active category). The continuous score is reported in median MET-minutes (metabolic equivalent of task-minutes). For categorical and continuous score is a higher score equivalent of higher physical functioning.
3 months
change of fitness assessed with IPAQ-sh (categories (1-3) and continues (MET-minutes))
Time Frame: 6 months
To examine the impact of a supervised training program on disease-related quality of life in patient with advanced prostate cancer compared to usual care. The following questionnaires are used: Short Hebrew International Physical Activity Questionnaire (IPAQ-sh). Both categorical and continuous indicators of physical activity will be used from the IPAQ short form. There are three categories:1. inactive, 2. minimally active, 3. HEPA active (health enhancing physical activity; a high active category). The continuous score is reported in median MET-minutes (metabolic equivalent of task-minutes). For categorical and continuous score is a higher score equivalent of higher physical functioning.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jean-Paul van Basten, Dr. MD, Canisius Wilhelmina Ziekenhuis (CWZ)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2024

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

May 1, 2025

Study Registration Dates

First Submitted

January 16, 2023

First Submitted That Met QC Criteria

February 20, 2024

First Posted (Actual)

February 28, 2024

Study Record Updates

Last Update Posted (Actual)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 20, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostatic Neoplasms

Clinical Trials on Physiotherapy

3
Subscribe